Pharmabiz
 

Depomed terminates agreement with Esprit Pharma for ProQuin XR

Menlo Park, CaliforniaSaturday, July 7, 2007, 08:00 Hrs  [IST]

Depomed, Inc. has ended the license agreement and the related supply and co-promotion agreements with Esprit Pharma for ProQuin XR, the extended release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections. Pursuant to the termination agreement, Esprit has paid Depomed $17,500,000. Esprit will also return the ownership of the Proquin NDA to Depomed along with all promotional materials. In addition, the parties have agreed to a detailed transition plan with specific activities and timelines related to the transition of the product from Esprit to Depomed. Depomed will leverage the commercial distribution network it has established for Glumetza to book sales and distribute Proquin in the US. "We are happy to have ProQuin back, said John W Fara, Ph.D., chairman, president and chief executive officer of Depomed. "We believe ProQuin will be a success, and we are continuing our discussions with potential new partners. We worked closely with Esprit to unwind the ProQuin agreements in a manner that assures our ability to continue commercialising ProQuin and appreciate their efforts in reaching this amicable agreement." ProQuin XR is a once-daily extended-release formulation of ciprofloxacin hydrochloride and is indicated to treat uncomplicated urinary tract infections (UTIs). UTIs are bacterial infections frequently caused by E coli and are typically treated with antibiotics.

 
[Close]